Trial Profile
A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Study 1
- Sponsors Roche
- 08 Nov 2019 Results (n=187) of exploratory analysis using pooled data from two clinical studies (NP28673 and NP28761) were published in the Journal of Thoracic Oncology
- 05 Jun 2018 Results (n=207) of an exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer patients using final pooled phase II OS and safety data (NCT01801111 and NCT01871805), presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results of a pooled analysis of NP28673 and NP28761 trials (n=225) assessing the survival and safety, presented at the 54th Annual Meeting of the American Society of Clinical Oncology